Bright Minds Biosciences Completes US$175Million Cross-Border Public Offering

Bright Minds Biosciences Inc. has completed an underwritten public offering of 1,945,000 common shares at US$90 per share, generating gross proceeds of approximately US$175.05 Million. The offering was conducted through a prospectus supplement to the company's U.S shelf registration statement on Form F-3 and included a 30-day option for the underwriters to purchase up to an additional 15% of the shares issued.

The financing represents Bright Minds' largest offering to date, helping drive the company's valuation above US$1 Billion and strengthening its position to advance its pipeline of novel therapies for neurological and psychiatric disorders.

The Vancouver-based biotechnology company is developing highly selective serotonergic compounds targeting significant unmet needs across areas including epilepsy, depression and other central nervous system disorders. The transaction involved coordinated Canadian and U.S securities law advice, supporting Bright Minds' continued growth in the North American capital markets.

Advisory Team:

McMillan LLP

Sasa Jarvis

Michael Shannon

Herbert I.Ono

Jordan Ghag

Habib Mavani

Anica Villamayor

Pablo Tseng